June 2026
Proprietary AI analyst is now available
Largest Diagnostics & Genomics Public Companies in South Korea
Benchmark revenue and EBITDA valuation multiples for public comps like
Abclon, ToolGen, Osang Healthcare, iNtRON Biotechnology and Genematrix.
 | Abclon Inc is engaged in the research and development of antibody drugs. Its business sector is divided into Antibody drug and Bio CRO. | $22 | +237% | $426M | $403M | 130.8x | (37.7x) | ||
| ToolGen Inc is a biotechnology company, which focuses on the development of genome editing technology. Its products include gRNA/Cas9 purified, gRNA/Cas9, and recombinant Cas9 protein, which offers ready-to-use reagents for genome engineering experiments. The company also offers genome-edited cell line; genome-edited mouse/rat; and genome-edited plant services, as well as surrogate reporter synthesis and in-del analysis services. | $33 | +66% | $294M | $278M | 325.6x | (12.5x) | ||
| Osang Healthcare Co Ltd is engaged in medical device development. It develops diagnostic biosensors for blood glucose measurement, HbA1c and cholesterol , Immuno Diagnosis, Molecular Diagnosis, etc. | $4 | -- | $62M | $69M | 0.8x | 9.2x | ||
| iNtRON Biotechnology Inc is a Korea-based company principally engaged in the biotechnology industry. It develops, manufactures, and commercializes drugs for the treatment of infectious diseases. It is contributing to national health and national prevention through several (molecular) diagnostic products such as swine flu, VRE super bacteria, food poisoning, avian influenza and foot, and mouth disease. In addition, it is also engaged in the operation of a veterinary antibiotic alternative business and new biopharmaceuticals development business. | $2 | -- | $53M | $33M | 8.7x | (7.1x) | ||
| Genematrix Inc is a biotech company engaged in the development of the platform and molecular diagnostics products. Its products include NeoPlexTM STI-7 Detection kit, OmniPlex-HPV, PapilloTyper, HepB Typer-Adefovir, and HepB Typer-Precore among others. | $1 | -- | $22M | $15M | 2.1x | (19.0x) | ||
| Median | $4 | +151% | $62M | $69M | 8.7x | (12.5x) |
Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.